Array Bio Pharma
|1885 33rd Street,
United States of America
Tel: 303 381 6600
Fax: 303 449 5376
Using proprietary software developed in-house, our scientists performed a retro-synthetic analysis of all the small molecules that have entered into clinical trials. The results of this analysis are represented in the Optimer™ collection. We have synthesized many of these building blocks as sets, which include the primary building block, useful for lead identification, and the secondary building blocks for SAR exploration around a lead.
Further Information: http://www.arraybiopharma.com
Related news from our archive
Array BioPharma and VentiRx Pharmaceuticals Announce License Agreement
VentiRx acquires exclusive worldwide rights to toll-like receptor program from Array to develop candidates in oncology and allergy.
Array BioPharma Announces Drug Discovery Collaboration With Ono Pharmaceutical
Ono will provide funding to access Array's Drug Discovery Platform.
Array BioPharma and Genentech Expand Strategic Oncology Collaboration
Both Companies collaborate for the discovery of targeted small molecule drugs for the treatment of cancer.